Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • JANX (NGM)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.

858 751 4493 10955 Vista Sorrento Parkway, San Diego, CA 92130, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Janux T-cell engager data sink stock, but analysts still see best-in-class potential - Fierce Biotech
Fierce Biotech • Dec 2
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's
Barron's • Dec 2
Janux Therapeutics CBO Meyer sells $25,798 in stock - Investing.com
Investing.com • Jan 3
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Yahoo Finance
Yahoo Finance • Dec 27
Charles Winter Sells 2,401 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
MarketBeat • Jan 3

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Janux Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Janux Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has approximately 109 employees.
What industry is Janux Therapeutics, Inc. in?
Janux Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Janux Therapeutics, Inc. a publicly traded company?
Yes, Janux Therapeutics, Inc. is publicly traded under the ticker symbol JANX on the NGM. The company has a market capitalization of approximately $0.86 billion.
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. is headquartered in San Diego, CA, United States at 10955 Vista Sorrento Parkway, San Diego, CA 92130, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.